<DOC>
	<DOCNO>NCT01219777</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) intravenous weekly paclitaxel give intravenous carboplatin bevacizumab patient epithelial ovarian , primary peritoneal , fallopian tube carcinoma receive neoadjuvant chemotherapy ( prior surgical cytoreduction ) . Patients undergo surgery allow objective measure response regimen well assessment surgical outcome .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab Primary Ovarian</brief_title>
	<detailed_description>Phase I study propose evaluate : - Tolerability IV regimen carboplatin , paclitaxel bevacizumab neoadjuvant set prior surgery . - Safety/Toxicity IV regimen patient population - Treatment Carboplatin area concentration curve ( AUC ) 5 , Bevacizumab 15mg/m2 , start dose paclitaxel 60mg/m2 escalate interval 10mg/m2 maximum dose 80mg/m2 . - Patients receive cycle 1-3 carboplatin , bevacizumab , paclitaxel cycle 4 carboplatin paclitaxel follow surgical intervention within 6 week cycle 4 . - Post surgical treatment per physician discretion</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histology , cytologically diagnose epithelial ovarian , primary peritoneal fallopian tube cancer FIGO ( International Federation Gynecology Obstetrics stage III IV disease GOG ( Gynecologic Oncology Group ) Performance Status 0,1,2 No prior surgery malignancy Adequate bone marrow function Platelet count great equal 100,000 Renal Function : Creatinine &lt; 1.5 institutional upper limit normal Hepatic Function : Bilirubin le 1.5 ULN ( upper limit normal ) Hepatic Function : SGOT ( serum glutamate oxaloacetate transaminase ) Alkaline Phosphate Neurologic Function : Neuropathy le CTCAE ( Common Toxicity Criteria Adverse Effects ) grade 1 Coagulation Functions : INR &lt; 1.5 PTT ,1.2 time upper limit normal Measurable disease Previous cancer relate surgery Received prior chemotherapy , immunotherapy , radiotherapy , hormonal therapy biologic therapy ovarian , fallopian tube primary peritoneal cancer . Borderline ovarian tumor , recurrent epithelial ovarian primary peritoneal cancer nonepithelial ovarian eligible . Other cancer within 5 year ( nonmelanoma skin cancer ) Acute Hepatitis end stage liver disease History prior gastrointestinal perforation Evidence abdominal free air explain paracentesis Sign symptoms gastrointestinal obstruction Active bleeding pathologic condition carry high risk bleed CNS ( Central Nervous System ) disease Clinically Significant cardiovascular disease Known hypersensitivity Chinese Hamster ovary cell product recombinant human humanize antibody Clinically significant proteinuria . Hypertensive crisis hypertensive encephalopathy History hemoptysis Any nonstudy related invasive procedure within 28 day fo first date bevacizumab GOG performance status 3 4 Patients pregnant nursing . Under age 18 Received prior treatment bevacizumab antiVEGF ( vascular endothelial growth factor ) drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>primary peritoneal</keyword>
</DOC>